Imaging tau pathology in Parkinsonisms

Abstract The recent development of positron emission tomography radiotracers targeting pathological tau in vivo has led to numerous human trials. While investigations have primarily focused on the most common tauopathy, Alzheimer’s disease, it is imperative that testing also be performed in parkinso...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah Coakeley, Antonio P. Strafella
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6afea461ad4e4fbcb28d678c014008db
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6afea461ad4e4fbcb28d678c014008db
record_format	dspace
spelling	oai:doaj.org-article:6afea461ad4e4fbcb28d678c014008db2021-12-02T12:33:37ZImaging tau pathology in Parkinsonisms10.1038/s41531-017-0023-32373-8057https://doaj.org/article/6afea461ad4e4fbcb28d678c014008db2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41531-017-0023-3https://doaj.org/toc/2373-8057Abstract The recent development of positron emission tomography radiotracers targeting pathological tau in vivo has led to numerous human trials. While investigations have primarily focused on the most common tauopathy, Alzheimer’s disease, it is imperative that testing also be performed in parkinsonian tauopathies, such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia and parkinsonism linked to chromosome 17. Tau aggregates differ in isoforms and conformations across disorders, and as a result one radiotracer may not be appropriate for all tauopathies. In this review, we evaluate the preclinical and clinical reports of current tau radiotracers in parkinsonian disorders. These radiotracers include [18F]FDDNP, [11C]PBB3, [18F]THK-5317, [18F]THK-5351, and [18F]AV-1451 ([18F]T807). There are concerns of off-target binding with [18F]FDDNP and [11C]PBB3, which may increase the signal to noise ratio and thereby decrease the efficacy of these radiotracers. Testing in [18F]THK-5317, [18F]THK-5351, and [18F]AV-1451 has been performed in progressive supranuclear palsy, while [18F]THK-5317 and [18F]AV-1451 have also been tested in corticobasal degeneration patients. [18F]THK-5317 and [18F]THK-5351 have demonstrated binding in brain regions known to be afflicted with pathological tau; however, due to small sample sizes these studies should be replicated before concluding their appropriateness in parkinsonian tauopathies. [18F]AV-1451 has demonstrated mixed results in progressive supranuclear palsy patients and post-mortem analysis shows minimal to no binding to non-Alzheimer’s disease tauopathies brain slices.Sarah CoakeleyAntonio P. StrafellaNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 3, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Sarah Coakeley Antonio P. Strafella Imaging tau pathology in Parkinsonisms
description	Abstract The recent development of positron emission tomography radiotracers targeting pathological tau in vivo has led to numerous human trials. While investigations have primarily focused on the most common tauopathy, Alzheimer’s disease, it is imperative that testing also be performed in parkinsonian tauopathies, such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia and parkinsonism linked to chromosome 17. Tau aggregates differ in isoforms and conformations across disorders, and as a result one radiotracer may not be appropriate for all tauopathies. In this review, we evaluate the preclinical and clinical reports of current tau radiotracers in parkinsonian disorders. These radiotracers include [18F]FDDNP, [11C]PBB3, [18F]THK-5317, [18F]THK-5351, and [18F]AV-1451 ([18F]T807). There are concerns of off-target binding with [18F]FDDNP and [11C]PBB3, which may increase the signal to noise ratio and thereby decrease the efficacy of these radiotracers. Testing in [18F]THK-5317, [18F]THK-5351, and [18F]AV-1451 has been performed in progressive supranuclear palsy, while [18F]THK-5317 and [18F]AV-1451 have also been tested in corticobasal degeneration patients. [18F]THK-5317 and [18F]THK-5351 have demonstrated binding in brain regions known to be afflicted with pathological tau; however, due to small sample sizes these studies should be replicated before concluding their appropriateness in parkinsonian tauopathies. [18F]AV-1451 has demonstrated mixed results in progressive supranuclear palsy patients and post-mortem analysis shows minimal to no binding to non-Alzheimer’s disease tauopathies brain slices.
format	article
author	Sarah Coakeley Antonio P. Strafella
author_facet	Sarah Coakeley Antonio P. Strafella
author_sort	Sarah Coakeley
title	Imaging tau pathology in Parkinsonisms
title_short	Imaging tau pathology in Parkinsonisms
title_full	Imaging tau pathology in Parkinsonisms
title_fullStr	Imaging tau pathology in Parkinsonisms
title_full_unstemmed	Imaging tau pathology in Parkinsonisms
title_sort	imaging tau pathology in parkinsonisms
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/6afea461ad4e4fbcb28d678c014008db
work_keys_str_mv	AT sarahcoakeley imagingtaupathologyinparkinsonisms AT antoniopstrafella imagingtaupathologyinparkinsonisms
_version_	1718393862925320192

Imaging tau pathology in Parkinsonisms

Ejemplares similares